Background
==========

Breast cancer is the most common malignant tumor in women with the highest morbidity and mortality among all malignant tumors in women. Surgery is one of the essential treatment approaches for breast cancer, together with endocrine therapy, adjuvant chemotherapy, radiotherapy, and immunotherapy. Neoadjuvant chemotherapy refers to systemic cytotoxic drug therapy before surgical treatment of patients with locally advanced malignant tumors, which has been an important part of comprehensive treatment of breast cancer, and aims to reduce primary tumors for breast conserving treatments, and control and eliminate systemic micro-metastases and subclinical disseminated lesions \[[@b1-medscimonit-25-3005]\]. Epidemiology studies have found that obesity, as a global health problem, is one of the important risk factors for breast cancer, especially for postmenopausal breast cancer and is closely related to the increase of breast cancer mortality \[[@b2-medscimonit-25-3005]\]. There is increasing evidence that obesity significantly contributes to cancer development, progression, and poor prognosis, particularly through the regulator adipokine leptin. Leptin is a small molecular protein encoded by the obese gene with a molecular weight of 16 kD. As an important adipocytokine, it plays an important role in regulating energy expenditure and the occurrence of obesity. Moreover, increased expression of leptin can induce the activation of a series of oncogenic signals, thereby promoting the occurrence and development of cancer \[[@b3-medscimonit-25-3005]\]. Leptin receptor (LEPR) is a product encoded by the LEPR gene. Leptin binds to LEPR to activate downstream signaling pathways. It has been reported that leptin and LEPR are overexpressed in breast cancer and have received much attention in recent years \[[@b4-medscimonit-25-3005]\]. Clinical studies have shown that increased leptin levels in obese patients might be a risk factor for breast cancer. With the increase of leptin, women are more likely to suffer highly malignant and poorly differentiated breast cancer. The higher the malignant degree of breast cancer is, the higher the expression of LEPR \[[@b5-medscimonit-25-3005]\], and the probability of poor prognosis is greatly increased \[[@b6-medscimonit-25-3005],[@b7-medscimonit-25-3005]\]. It has also been reported that leptin binding to its receptor can not only promote cell proliferation, inhibit apoptosis, but also induce angiogenesis and promote breast cancer metastasis by regulating multiple signaling pathways including JAK/STAT3, MAPK/ERK1/2, PI3K/AKT, PKC, JNK, and p38 \[[@b8-medscimonit-25-3005]\]. However, the relationship between leptin and its receptors and the efficacy of breast cancer treatment is unclear. Studies have found that obesity is an independent prognostic factor for the reduction of pathologic complete response (PCR) to neoadjuvant chemotherapy in breast cancer patients. It was reported that a decrease of complete response rate as well as shortening of progression-free survival (PFS) and overall survival was found in obese breast cancer patients compared with patients with normal or light weight after treatment of neoadjuvant chemotherapy, but the effect of leptin on the treatment of breast cancer has not been clarified \[[@b9-medscimonit-25-3005]\]. This study explored the correlation of leptin as well as its receptor LEPR with the efficacy of neoadjuvant chemotherapy for breast cancer, and evaluated its predictive value for the efficacy and prognosis of neoadjuvant chemotherapy.

Material and Methods
====================

Patients
--------

There were 325 breast cancer patients who were treated with neoadjuvant chemotherapy at the Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province) from January 2014 to December 2017 who were enrolled in this study. There were 67 cases with PCR and 258 cases with non-pathological complete response (NPCR) in which 40 cases were progressive disease (PD). Surgical specimens were used for pathological response evaluation after neoadjuvant chemotherapy. Pathological results were determined by 2 pathologists using double-blind method according to the Miller and Payne scoring system. PCR was defined as no tumor residual in both the breast and the armpit. All patients received radical surgery treatment and the pathological data were complete. The age of the patients ranged from 27 years to 71 years, with an average age of 51 years. The clinicopathological features are shown in [Table 1](#t1-medscimonit-25-3005){ref-type="table"}. Patients were categorized into 3 groups in accordance with treatment efficacy: PCR group, NPCR group, and PD group. This study was approved by the ethics committee of the Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province) and written informed consent were obtained from all patients.

Immunohistochemistry
--------------------

The enrolled 325 cases had a coarse needle biopsy to extract a specimen of tumor tissue. The obtained specimen was embedded in paraffin using routine procedures with immunohistochemistry performed using the SP method (streptavidin peroxidase conjugate method) to stain for leptin and LEPR. Leptin rabbit anti-human polyclonal antibody (ab16227, Abcam, Cambridge, UK) and LEPR rabbit anti-human polyclonal antibody (ab104403, Abcam, Cambridge, UK) were diluted to l: 200. Paraffin sections were cut to about 4 μm slices, dewaxed with conventional xylene, gradient alcohol hydrated and citrate buffer pH 6.0. Then high temperature and high-pressure antigen treatment for 2 minutes. After natural cooling, 10% deionized water solution was as a blocked for 15 minutes. Then sheep serum was added and incubated at 37°C for 20 minutes. The primary antibody was added and incubated at 4°C overnight. After rewarming for 1 hour, we added biotin-labeled secondary antibody and incubated at 37°C for 30 minutes, then added horseradish peroxidase-labeled streptomycin avidin and incubated at 28°C for 30 minutes. The section was washed with 10% PBS 3 times for 5 minutes each time. Freshly prepared DAB solution was added to the section and the coloration result was observed under a microscope. After color development ending, the hematoxylin stain was counterstained for 1--5 minutes, hydrochloric acid was used for differentiation, gradient alcohol was used for dehydration after washing, then xylene was applied, and neutral gum was used to seal the section. Then the section was observed under the microscope. Positively expressed tissue sections were used as the positive controls, and PBS was used instead of primary antibody as the negative control.

Evaluation and judgment of pathological results
-----------------------------------------------

Pathological results were determined by 2 pathologists using double-blind method according to the following criteria. When the judgment of the 2 pathologists was severely biased, a third pathologist was consulted. If agreement still could not be reached, the case would be excluded. A 5 high power field was used for the evaluation of leptin and its receptor LEPR. The expression of leptin and its receptor LEPR were localized to the cytoplasm and stained yellow or brownish yellow. The evaluation was assessed by semi-quantitative method. Sections were scored from 2 aspects: proportion of staining cells and staining intensity. There were 4 levels according to the proportion of staining cells which were 0 (negative, 0%), 1 (positive, \<10%), 2 (positive, 11--50%), 3 (positive, 51--75%), and 4 (positive, \>75%). From staining intensity, sections were scored into 3 levels: 0 (no staining), 1 (light yellow), 2 (dark yellow), and 3 (dark brown). The final score was obtained by multiplying the percentage of positive cells by the staining intensity and was categorized into 4 grades which were \<2, 3--5, 6--8, and ≥9 which indicated negative, weak positive (+), positive (++), and strong positive (+++), respectively \[[@b10-medscimonit-25-3005]\].

Statistical analysis
--------------------

The different expression levels of leptin and its receptor LEPR which included negative, weak positive, positive, and strong positive, were compared by nonparametric test, Mann-Whitney U and Kruskal-Wallis H test. Comparison of disease progression between PCR and NPCR group and its comparison between leptin and LEPR high expression and low expression group were performed by χ^2^ test and Fisher's exact test. The package SPSS 21.0 was used for statistical analysis. *P*\<0.05 was considered statistically significant.

Results
=======

Leptin and LEPR expression between PCR and NPCR group
-----------------------------------------------------

In the PCR group, the cases with weak positive, positive, and strong positive leptin expression were 12 cases (17.9%), 11 cases (16.4%), and cases 29 (43.3%) respectively, while there were 15 (22.4%) negative cases As for the LEPR, there were 23 cases (34.3%) with strong positive expression, 29 cases (43.3%) with positive expression, 11 cases (16.4%) with weak positive expression, and 4 cases (6.0%) with negative expression. In the NPCR group with 258 cases in total, the expression of leptin was as follows 34 cases (13.2%) were strong positive expression, 92 cases (35.7%) were positive, 66 cases (25.6%) were weak positive, and 66 cases (25.6%) were negative. The LEPR expression was as follows: 73 cases (28.3%) strong positive, 104 cases (40.3%) positive, 43 cases (16.7%) weak positive, and 38 cases (14.7%) negative. The strong and positive strong expression of both leptin and LEPR in PCR group were higher than that in the NPCR group, but the difference was not statistically significant (*P*=0.194, *P*=0.110). There was no distinction between the PCR group and the NPCR group in leptin and LEPR expression ([Figures 1](#f1-medscimonit-25-3005){ref-type="fig"}, [2](#f2-medscimonit-25-3005){ref-type="fig"}, [Table 2](#t2-medscimonit-25-3005){ref-type="table"}).

Leptin and LEPR expression between the PCR group and the PD group
-----------------------------------------------------------------

Among the 40 cases in the PD group, the patients with the strong positive, positive, weak positive, and negative expression of leptin respectively were 4 cases (10.0%), 11 cases (27.5%), 13 cases (32.5%), and 12 cases (30.0%). As for LEPR, there were 7 cases (17.5%) with strong positive expression, 15 cases (37.5%) with positive expression, 11 cases (27.5%) with weak positive expression, and 4 cases (17.5%) with negative expression. The strong positive and positive expression of both leptin and LEPR in the PCR group were higher than that in the PD group, in which the difference of leptin expression was statistically significant (*P*=0.008) but the expression of LEPR was not (*P*=0.065). The results indicated patients with high LEPR expression received better therapeutic efficacy ([Table 3](#t3-medscimonit-25-3005){ref-type="table"}).

Leptin and LEPR expression of patients with different breast cancer molecular subtypes between the PCR group and the PD group
-----------------------------------------------------------------------------------------------------------------------------

Among the 325 participants, 136 participants were human epidermal growth factor receptor 2 positive (HER2+), 123 participants were hormone receptor positive (HR+), and 66 participants were triple negative. The leptin and LEPR expression of patients with HR+ and triple negative breast cancer in the PCR group were higher than that in the PD group but not statistically different (*P*\>0.05). The patients undergoing HER+ breast cancer in the PCR group with strong positive, positive, weak positive, and negative expressed leptin were 9 patients (25.0%), 15 patients (41.7%), 4 patients (11.1%), and 8 patients (22.2%), respectively. The situation of LEPR expression in the PCR group was: 17 patients (47.2%) were strong positive, 12 patients (33.3%) were positive, 6 patients (16.7%) were weak positive, and 1 patient (2.8%) was negative. Among patients undergoing HER+ breast cancer in the PD group, 1 patient (8.3%), 2 patients (16.7%), 5 patients (41.7%), and 4 patients (33.3%) were strong positive, positive, weak positive, and negative expressed of leptin while 1 patient (8.3%), 7 patients (58.3%), 2 patients (16.7%), and 2 patients (16.7%) were strong positive, positive, weak positive, and negative expression of LEPR, respectively. Positive and strong positive expression of leptin and LEPR was superior in the PCR group to that in the PD group (*P*=0.049, *P*=0.025). HER+ breast cancer patients with greater expression of leptin and LEPR received preferred therapeutic outcome ([Tables 4](#t4-medscimonit-25-3005){ref-type="table"}[](#t5-medscimonit-25-3005){ref-type="table"}--[6](#t6-medscimonit-25-3005){ref-type="table"}).

Leptin and LEPR expression in breast cancer cases with different molecular subtypes
-----------------------------------------------------------------------------------

The positive expression rate (including positive and strong positive) of leptin in patients with HER+, HR+, and triple negative breast cancer were 57.4%, 39.1%, and 60.6%, respectively. The positive expression rate of LEPR of patients with HER+ HR+, and triple negative breast cancer were 73.5%, 61.0%, and 81.8%. In comparison, leptin and LEPR expression of triple negative breast cancer cases were more than that of cases with HER2+ or HR+ breast cancer (*P*\<0.01, [Table 7](#t7-medscimonit-25-3005){ref-type="table"}).

Progressive disease (PD) and overall survival
---------------------------------------------

As of December 1, 2018, there were 45 patients among 325 with PD and 23 deaths. In the PCR group, there were 5 patients (7.46%) with PD, while 40 patients (15.5%) in the NPCR group. The PD rate of patients with high and low expressed of leptin and LEPR were 13.25% versus 11.32% and 13.1% versus 10.42%, indicating the prognosis with high expression of leptin and LEPR might be worse, but the difference was not statistically significant (*P*\>0.05, [Tables 8](#t8-medscimonit-25-3005){ref-type="table"}, [9](#t9-medscimonit-25-3005){ref-type="table"}).

Discussion
==========

Leptin is a protein product encoded by the obese gene, containing 167 amino acids and as an important adipose cell cytokine, it is closely related to obesity. In addition to regulating food intake and energy balance, leptin plays a significant role in promoting tumor invasion, metastasis, neovascularization, and epithelial-mesenchymal transition by binding to LEPR \[[@b11-medscimonit-25-3005],[@b12-medscimonit-25-3005]\]. It has been reported in many studies to be crucial for the development of various malignant tumors. The effect of leptin and LEPR on the treatment of breast cancer has received many concerns due to its high correlation with obesity and that obesity is closely associated with breast cancer. Some *in vivo* and *in vitro* experiments suggested that leptin and LEPR were contributing factors to the development of breast cancer \[[@b13-medscimonit-25-3005]--[@b15-medscimonit-25-3005]\], while other studies found no significant correlation between leptin and breast cancer \[[@b16-medscimonit-25-3005]\]. But the leptin and LEPR acting in the onset and therapeutics of breast cancer has not been thoroughly defined for inadequate direct evidence to favor the causality between leptin and LEPR expression.

Del Fabbro et al. reported overweight patients receiving neoadjuvant therapy had lower PCR rates and shorter PFS times \[[@b9-medscimonit-25-3005],[@b17-medscimonit-25-3005]\]. Karatas et al. \[[@b9-medscimonit-25-3005]\] suggested leptin was an independent prognostic factor for the reduction of PCR to neoadjuvant chemotherapy in breast cancer patients. But the effect of leptin on the therapeutic efficacy has not consistently reported. Slomian et al. \[[@b18-medscimonit-25-3005]\] found that serum adiponectin and leptin levels were not associated with chemotherapy response to ovarian cancer. Bain et al. \[[@b19-medscimonit-25-3005]\] presented a study analyzing the neoadjuvant chemotherapy treatment of gastric cancer and found a higher TRG4-5 expression compared with TRG1-3 and showed a close correlation of high expression of leptin with poor PCR to neoadjuvant chemotherapy. Méndez-Hernández et al. \[[@b20-medscimonit-25-3005]\] found that the polymorphisms of leptin rs7799039 and ADIPOQ rs1501299 were associated with overweight/obesity, and obese patients were more likely to have no response to chemotherapy. In this study, leptin and LEPR expression of patients with PCR was higher than that with NPCR after neoadjuvant chemotherapy treatment, and the difference of leptin and LEPR expression between patients with PCR and PD inclined greater. The difference in expression of LEPR was statistically significant. It might be because patients with high leptin and LEPR expression were more likely to experience tumor invasion and metastasis and thus these patients were more susceptible to chemotherapy.

Further comparison among patients with different molecular types revealed that HER2+ breast cancer patients with high leptin and LEPR expression had better therapeutic effects, and the difference was statistically significant. Ray et al. \[[@b21-medscimonit-25-3005]\] found that leptin could activate HER/neu receptor in breast cancer cells. Suimacz et al. \[[@b22-medscimonit-25-3005]\] reported co-expression of HER2 with leptin and LEPR might enhance the activity of HER2 in a study of multiple cell lines and 59 cases of tumor tissues of breast cancer. In addition, Wang et al. \[[@b23-medscimonit-25-3005]\] found LEPR were associated with HER2 expression and might be a leading cause of the poor prognosis in breast cancer. This might explain why neoadjuvant chemotherapy received a better efficacy in HER+ patients with high leptin and LEPR expression.

The current study also initiated the expression distinction of leptin and LEPR among breast cancer patients with different subtypes. The expression of triple negative and HER2+ patients was greater than that with HR+, in which leptin and LEPR expression in triple negative patients was the highest. Previous studies have found that persistent obesity increases the risk of triple negative and HR+ breast cancer, and the effect on the triple negative type is more obvious \[[@b24-medscimonit-25-3005]\].

Méndez-Hernández et al. suggested the higher levels of leptin were found in HR+ specimens \[[@b20-medscimonit-25-3005]\]. Wang et al. \[[@b23-medscimonit-25-3005]\] indicated that LEPR expression was not associated with estrogen receptor and progesterone receptor expression but related to the expression of HER2. Whereas, Wang et al. \[[@b25-medscimonit-25-3005]\] found that LEPR expression was no significantly difference among breast cancer subtypes. Hence, the expression of them in different molecular subtypes remains arguable and commitment to be confirmed by further studies.

Previous clinical studies have found that patients with an increase of leptin often receive poor prognosis \[[@b26-medscimonit-25-3005]--[@b28-medscimonit-25-3005]\]. There is no uniform conclusion about the effect of LEPR on the prognosis of early breast cancer. Some studies suggested the overall survival and disease-free survival were significantly shortened in breast cancer patients with high expression of LEPR \[[@b13-medscimonit-25-3005]\]. Conversely, another study showed that LEPR expression levels were not associated with disease-free survival and overall survival \[[@b25-medscimonit-25-3005]\]. In our study, there were 45 cases with PD and 23 deaths. The PD rate of patients with leptin and LEPR overexpression was higher than that with low expression, suggesting that overexpression of leptin and LEPR might be the sign of poor prognosis. The follow-up time was short in this study, and it could not exclude the possibility of the incidence of significant difference between the 2 groups with the extension of follow-up time.

Conclusions
===========

High expression of leptin and its receptor LEPR might lead to better therapeutic efficacy of neoadjuvant chemotherapy for breast cancer patients, especially for patients with HER2+ breast cancer. High expression of leptin and LEPR were different among patients with different molecular subtypes of breast cancer, which might have a certain predictive value for the prognosis.
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###### 

Clinic or pathological parameter.

  ------------------------------- ---------------
  Mean age at diagnosis (years)   50.8 (27--71)
  Menopausal status               N=325 (%)
   Pre                            170 (52.3)
   Post                           155 (47.7)
  Clinical stage                  
   I                              54 (16.6)
   II                             131 (40.3)
   III                            140 (43.1)
  Tumor size at baseline          
   T1                             210 (64.6)
   T2                             95 (29.2)
   T3                             17 (5.2)
   T4                             3 (1.0)
  Node status at baseline         
   −                              34 (10.5)
   +                              291 (89.5)
  Breast cancer subtype           
   HR+                            123 (37.8)
   HER2+                          136 (41.8)
   Triple negative                66 (20.4)
  Curative effect                 
   PCR                            67 (20.6)
   NPCR                           258 (79.4)
   PD                             40 (12.3)
  ------------------------------- ---------------

HR+ -- hormone receptor positive; HER2+ -- human epidermal growth factor receptor 2 positive; PCR -- pathological complete response; NPCR -- non-pathological complete response; PD -- progressive disease.

###### 

The expression of leptin and leptin receptor in PCR and NPCR group.

  Group   n (%)   Leptin      *P* value   Leptin receptor   *P* value                                                                
  ------- ------- ----------- ----------- ----------------- ----------- ----------- ----------- ------------ ----------- ----------- -------
  PCR     67      15 (22.4)   12 (17.9)   29 (43.3)         11 (16.4)   0.194       4 (6.0)     11 (16.4)    29 (43.3)   23 (34.3)   0.110
  NPCR    258     66 (25.6)   66 (25.6)   92 (35.7)         34 (13.2)   38 (14.7)   43 (16.7)   104 (40.3)   73 (28.3)               

PCR -- pathological complete response; NPCR -- non-pathological complete response.

###### 

The expression of leptin and leptin receptor in PCR and PD group.

  Group   n (%)   Leptin      *P* value   Leptin receptor   *P* value                                                              
  ------- ------- ----------- ----------- ----------------- ----------- ---------- ----------- ----------- ----------- ----------- -------
  PCR     67      15 (22.4)   12 (17.9)   29 (43.3)         11 (16.4)   0.065      4 (6.0)     11 (16.4)   29 (43.3)   23 (34.3)   0.008
  PD      40      12 (30.0)   13 (32.5)   11 (27.5)         4 (10.0)    7 (17.5)   11 (27.5)   15 (37.5)   7 (17.5)                

PCR -- pathological complete response; PD -- progressive disease.

###### 

The expression of leptin and leptin receptor of patients with HR+ in PCR and PD group.

  Group   n (%)   Leptin     *P* value   Leptin receptor   *P* value                                                          
  ------- ------- ---------- ----------- ----------------- ----------- ---------- ---------- ---------- ---------- ---------- -------
  PCR     12      3 (25.0)   6 (50.0)    3 (25.0)          0 (0)       0.433      1 (8.3)    4 (33.3)   5 (41.7)   2 (16.7)   0.067
  PD      13      6 (46.2)   4 (30.8)    3 (23.1)          0 (10.0)    4 (30.8)   6 (46.2)   2 (15.4)   1 (7.7)               

HR+ -- hormone receptor positive; PCR -- pathological complete response; PD -- progressive disease.

###### 

The expression of leptin and leptin receptor of patients with HER2+ in PCR and PD group.

  Group   n (%)   Leptin     P value    Leptin receptor   P value                                                             
  ------- ------- ---------- ---------- ----------------- ---------- ---------- ---------- ---------- ----------- ----------- -------
  PCR     36      8 (22.2)   4 (11.1)   15 (41.7)         9 (25.0)   0.049      1 (2.8)    6 (16.7)   12 (33.3)   17 (47.2)   0.025
  PD      12      4 (33.3)   5 (41.7)   2 (16.7)          1 (8.3)    2 (16.7)   2 (16.7)   7 (58.3)   1 (8.3)                 

HER2+ -- human epidermal growth factor receptor 2 positive; PCR -- pathological complete response; PD -- progressive disease.

###### 

The expression of leptin and leptin receptor of patients with triple negative in PCR and PD group.

  Group   n (%)   Leptin     *P* value   Leptin receptor   *P* value                                                          
  ------- ------- ---------- ----------- ----------------- ----------- --------- ---------- ---------- ----------- ---------- -------
  PCR     19      4 (21.1)   2 (10.5)    11 (57.9)         2 (10.5)    0.866     2 (10.5)   1 (5.3)    12 (63.2)   4 (21.1)   0.849
  PD      15      2 (13.3)   4 (26.7)    6 (40.0)          3 (20.0)    1 (6.7)   3 (20.0)   6 (40.0)   5 (33.3)               

PCR -- pathological complete response; PD -- progressive disease.

###### 

The expression of leptin and leptin receptor in patients with different molecular breast cancer subtypes.

  Group             n (%)   Leptin      *P* value   Leptin receptor   *P* value                                                              
  ----------------- ------- ----------- ----------- ----------------- ----------- ---------- ----------- ----------- ----------- ----------- -------
  HR+               123     41 (33.3)   34 (27.6)   44 (35.8)         4 (3.3)     \<0.001    22 (17.9)   26 (21.1)   53 (43.1)   22 (17.9)   0.001
  HER2+             136     28 (20.6)   30 (22.1)   51 (37.5)         27 (19.9)   13 (9.6)   23 (16.9)   49 (36.0)   51 (37.5)               
  Triple negative   66      12 (18.2)   14 (21.2)   26 (39.4)         14 (21.2)   7 (10.6)   5 (7.6)     31 (47.0)   23 (34.8)               

HR+ -- hormone receptor positive; HER2+ -- human epidermal growth factor receptor 2 positive.

###### 

Progression disease in PCR and NPCR group.

  Group   n (%)   Progression disease   *P* value    
  ------- ------- --------------------- ------------ -------
  PCR     67      5 (7.5)               62 (92.5)    0.090
  NPCR    258     40 (15.5)             218 (84.5)   

PCR -- pathological complete response; NPCR -- non-pathological complete response.

###### 

Progression disease at different expression levels of leptin and leptin receptor.

  Group                       n (%)                   Progression disease   *P* value                 
  --------------------------- ----------------------- --------------------- ------------ ------------ -------
  Leptin                      Low expression (−\~+)   159                   18 (11.3)    141 (88.7)   0.596
  High expression (++\~+++)   166                     22 (13.3)             144 (86.7)                
  Leptin receptor             Low expression (−\~+)   96                    10 (10.4)    86 (89.6)    0.502
  High expression (++\~+++)   229                     30 (13.1)             199 (86.9)                
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